Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen Cryptococcus neoformans
Marie Desnos-Ollivier, Sweta Patel, Adam Spaulding, Caroline Charlier, Dea Garcia-Hermoso, Kirsten Nielsen, Françoise Dromer

To cite this version:
Marie Desnos-Ollivier, Sweta Patel, Adam Spaulding, Caroline Charlier, Dea Garcia-Hermoso, et al.. Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen Cryptococcus neoformans. mBio, American Society for Microbiology, 2010, 1 (1), pp.e00091-10. 10.1128/mBio.00091-10. pasteur-02195111

HAL Id: pasteur-02195111
https://hal-pasteur.archives-ouvertes.fr/pasteur-02195111
Submitted on 26 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike| 4.0 International License
Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen Cryptococcus neoformans

Marie Desnos-Ollivier,a,b Sweta Patel,a,b Adam R. Spaulding,c Caroline Charlier,a,b Dea Garcia-Hermoso,a,b Kirsten Nielsen,c and Françoise Dromer,a,b

Molecular Mycology Unit, Institut Pasteur, Paris, Francea; CNRS URA3012, Paris, Franceb; and Department of Microbiology, Medical School, University of Minnesota, Minneapolis, Minnesota, USAa

M.D.-O. and S.P. are co-first authors.

ABSTRACT Koch’s postulates are criteria establishing a causal relationship between a microbe and a disease that lead to the assumption that diseases are caused by a single strain or its evolved forms. Cryptococcus neoformans is a life-threatening human fungal pathogen responsible for an estimated 1 million cases of cryptococcosis/year, predominantly meningoencephalitis. To assess the molecular diversity of clinical isolates and gain knowledge of C. neoformans biology in the host, we analyzed clinical cultures collected during the prospective CryptoA/D study. Using molecular analysis of unpurified isolates, we demonstrated that mixed infections in humans are more common than previously thought, occurring in almost 20% of patients diagnosed with cryptococcosis. These mixed infections are composed of different mating types, serotypes, and/or genotypes. We also identified genetically related haploid and diploid strains in the same patients. Experimental infections and quantitative PCR show that these ploidy changes can result from endoreplication (duplication of DNA content) and that shuttling between haploid and diploid states can occur, suggesting in vivo evolution. Thus, the concept of one strain/one infection does not hold true for C. neoformans and may apply to other environmentally acquired fungal pathogens. Furthermore, the possibility of mixed and/or evolving infections should be taken into account when developing therapeutic strategies against these pathogens.

IMPORTANCE Cryptococcus neoformans is a life-threatening human fungal pathogen that is present in the environment and is responsible for an estimated 1 million cases of cryptococcosis/year, predominantly meningoencephalitis in HIV-infected patients. To assess the molecular diversity of clinical isolates and gain knowledge of C. neoformans biology in the host, we analyzed clinical cultures collected during a prospective study on cryptococcosis. Using molecular analysis of unpurified isolates, we uncovered an unexpectedly high frequency (almost 20%) of mixed infections. We further demonstrated that these mixed infections could result from infestation by multiple strains acquired from the environment. We also made the serendipitous discovery of in vivo evolution leading to endoreplication of the yeasts within the host. Thus, the concept of one strain causing one infection does not hold true for C. neoformans and potentially for other environmentally acquired fungal pathogens. The possibility of mixed and/or evolving infections should be taken into account when developing therapeutic strategies against these pathogens.

Cryptococcus neoformans is a haploid encapsulated yeast responsible for cryptococcosis, an opportunistic infection that occurs in patients with cellular immune defects, especially those with AIDS. Cryptococcosis affects up to 30% of HIV-infected patients in sub-Saharan Africa and Southeast Asia (1). Overall, cryptococcal meningoencephalitis is diagnosed in almost 1 million individuals per year, accounting for more than 600,000 deaths annually (2). Cryptococcosis is still fatal in almost 20% of cases despite adequate treatment, justifying the development of new therapeutic strategies. C. neoformans is ubiquitous in the environment, particularly in bird droppings and decaying vegetation. It exists in two varieties, C. neoformans var. grubii (serotype A), which causes the majority of infections worldwide, and C. neoformans var. neoformans (serotype D), which is commonly found in Europe. Cryptococcosis is usually considered to represent the reactivation of a dormant infection (1). A single isolate of C. neoformans has been thought to be responsible for the disease. Yet the isolation of strains with different genotypes, serotypes, or mating types at the same geographic site (3, 4) makes infestation by multiple strains likely. Only anecdotal reports of mixed infections have been published to date. In mixed infections involving different species or serotypes of Cryptococcus, multiple single-colony isolates were analyzed due to vastly different colony morphologies (5, 6). In other cases, different genotypes of C. neoformans var. grubii have been identified in temporally separated single-colony isolates during the same episode or during a relapse of infection (7–11). Microevolution during infection has been suggested and shown to occur during long-term storage and repeated passage in the labo-
Previous studies have cited the need for large-scale studies to be carried out with unpurified isolates to determine the true incidence of mixed infections (6, 15) because routine clinical practice (storage of a single colony per isolate, one isolate studied per patient, and no routine detection of ploidy or mating type) precludes the discovery of mixed infections.

Identification of sexual cycles in the pathogenic fungi greatly expanded our understanding of their biology (16–18). The sexual cycle of *C. neoformans* involves mating types a and α (MATa and MATα), but sexual reproduction seems limited by apparently rare encounters with sexual partners (17, 19). However, recombination is observed, potentially due to monokaryotic fruiting following same-sex cell fusion or self-diploidization (also called endoreplication) with the production of recombinant haploid or diploid progenies (20–23). AD hybrid strains of *C. neoformans* var. *neoformans* and *grubii* have also been identified. These hybrids can harbor both mating types or result from same-sex mating (24, 25). Hybrids have been observed in nature and in clinical samples and have been generated in the laboratory (26, 27). The ability to undergo mating or endoreplication is assumed to allow response to environmental and host challenges and contributes to genetic diversity (28). To date, experimental infections with laboratory reference strains have not revealed stable ploidy changes (29).

The scarcity of mixed-infection reports could be explained either by their true rarity or by the fact that most clinical isolates are single colony purified prior to molecular analysis. Our objective was to analyze isolates that were not colony purified to determine the frequency of mixed infections and if AD hybrid formation, mating, or monokaryotic fruiting could occur in vivo because of the simultaneous presence of multiple strains. For these analyses, we used a collection of clinical isolates that were sent unpurified to the French National Reference Center for Mycoses and Antifungals (NRCMA) during the prospective CryptoA/D study (30). Our analysis represents the first estimate of mixed infections during cryptococcosis. Various combinations of strains with different mating types, serotypes, ploidies, and genotypes were found during the same episode of cryptococcosis, sometimes in the same sample. While mating and hybrid formation could not be demonstrated in vivo, diploidization resulting from endoreplication was documented and enhanced the diversity of infecting strains.

**RESULTS**

**Mixed infections are frequent and diverse during cryptococcosis.** We examined 100 isolates corresponding to 49 patients for whom *C. neoformans* unpurified original cultures had been stored during the CryptoA/D study (30). Single-colony isolates (4 to 33 single colonies/culture) were screened for all 100 cultures. Original cultures and single-colony isolates were analyzed for ploidy by flow cytometry, and genotypes were determined by amplification of serotype- and mating-type-specific loci by PCR.

Mixed infections were demonstrated for 9/49 patients studied (18.4%). A total of 31 original cultures (15 from cerebrospinal fluid [CSF] samples, 10 from blood cultures, 4 from urine samples, 1 from a skin lesion, and 1 from a bronchoalveolar lavage [BAL] fluid sample) and 286 single-colony isolates from these nine patients were studied. Among the 31 original cultures, 8 were found to be diploid and 23 were haploid (Table 1). Subsequent analysis of single-colony isolates derived from the eight diploid cultures showed that strains with different ploidies, serotypes, or mating types could be found in the same culture for six patients (Table 1). Different strains were also found at different anatomical sites and at different time points during infection (up to 15 days) for seven patients. Using multilocus sequence typing (MLST), infection by two genetically distinct isolates of *C. neoformans* var. *grubii* was found for one patient (no. 188) with differences in 4/8 loci (Table 1). Overall, mixed infections with different serotypes, mating types, ploidies and/or genotypes in various combinations were observed as follows: Aα + Da (patient no. 188), Aα + Da (no. 71), Aα + αDAa (no. 10 and 198), Aα + αAaα (no. 161), Aα + αDDα (no. 20 and 23), Da + αDDa (no. 119), and Aα + Dα + αADα + αDDα (no. 177). Patients with mixed infections did not differ significantly from those with single infections in terms of underlying disease and clinical presentation. However, a trend toward more mycological failures after 2 weeks of antifungal treatment but reduced mortality was observed in the mixed-infection group (Table 2).

**Multiple infestations are responsible for mixed infections during cryptococcosis.** The discovery of haploid and AD hybrid diploid isolates in the same patient suggested that either these ploidy changes occurred in the environment with subsequent inhalation of multiple strains or they occurred within the human host. MLST analysis was used to differentiate between these two possibilities. Three patients (no. 177, 10, and 198) had infections with haploid Aα and diploid αADα or αDa hybrid strains. MLST analysis of these three serotype A polymorphic loci revealed that in all cases the Aα alleles differed between the haploid and the hybrid strains (Table 1). These results ruled out genetic relatedness between the A and AD isolates and showed that the haploid Aα could not have arisen from unstable AD diploids that dropped the D portion of their genome. These results, together with the discovery of serotype A and D strains during the same episode of cryptococcosis in five patients (no. 20, 23, 71, 177, and 188), provided evidence for coinfection with genetically distinct strains acquired from the environment.

**Diploidization can occur in vivo to generate mixed infections during cryptococcosis.** In four patients infected with both haploid and diploid Aα (no. 161), Da (no. 71 and 119), or Dα (no. 177) strains, the infections could have resulted from either co-infection with genetically unrelated or related strains or in vivo diploidization through same-sex cell fusion or endoreplication. The Aα haploid and diploid strains had the same MLST profile (Table 1). Haploid and diploid serotype D strains from the same patient shared the same MLST profile, even though each patient was infected with an evolutionarily distinct strain (Table 1). Given the observed genotypic diversity of strains (six genotypes recorded for nine patients infected with serotype A strains and five genotypes for six patients infected with serotype D strains), the most likely explanation for the genetic relatedness between the haploid and diploid isolates is either cell fusion between genetically identical cells or endoreplication within the host or in nature.

To determine whether these ploidy changes could have occurred *in vivo*, we infected mice with the Aα haploid single-colony isolate (AD 7-99, patient no. 161) in two independent experiments. Two diploid Aα strains out of 330 single colonies studied were recovered from two mouse brains at 9 and 15 days postinoculation (Fig. 1a). They were genetically identical to AD 7-99 by MLST analysis. Interestingly, while the patient-derived haploid and diploid single-colony isolates were equally virulent in mice, a
same nucleotide sequences for the
and
CAP10/H11021
mouse-derived diploid strain had attenuated virulence (Fig. 1b, P < 0.001).

We then assessed whether diploid strains were stable in vivo. Groups of mice were inoculated with the clinical diploid Aα strain

### TABLE 1 Molecular characteristics of C. neoformans isolates causing mixed infections in nine patients with cryptococcosis

| Patient no. | Site of isolation | Days since 1st positive culture | Serotype/mating type | No. studied | Ploidyb | Serotype/mating type | Single colonies | MLST profilec |
|-------------|------------------|---------------------------------|----------------------|-------------|---------|----------------------|----------------|--------------|
| 188 | CSF | 0 | n, Aα | 5 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-26 | Blood | 4 | n | Dα | 5 | n | Dα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-35 | CSF | 0 | n | Aα | 5 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-26 | Blood | 0 | n | Aα | 5 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-27 | Blood | 5 | n | Aα | 4 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-28 | Blood | 6 | n | Aα | 4 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-29 | Blood | 9 | n | Aα | 4 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-30 | Blood | 11 | n | Aα | 5 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-21 | BAL fluid | 12 | n | Aα | 4 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |
| AD 1-31 | BAL fluid | 24 | n | Aα | 4 | n | Aα | 7/11/13/9/19/11 | CAP59/URA5/GPD1/SOD1/LAC1/IGS1/PLB1/TEF1 |

**Notes:**

- Original culture, unpurified culture from clinical sample; single colony, purified single colony from corresponding clinical culture.
- Ploidy was determined by flow cytometry; n, haploid; 2n, diploid.
- Genotypes were determined for serotype A and serotype D isolates by using eight loci selected by the MLST method. For AD hybrid isolates, allelic profiles were determined for
CAP10 and URE1 (27) and for SOD1, PLB1, and TEF1 loci with serotype A-specific primers specifically designed for this study. All of the AD hybrid and Aα strains studied had the same nucleotide sequences for the CAP10 and URE1 loci. New alleles are in bold italics, serotype D alleles are underlined, and serotype A alleles are without underlining.
TABLE 2 Characteristics of patients with and without mixed cryptococcal infections

| Patient characteristic | Mixed infection (n = 9) | No mixed infection (n = 40) | P value |
|------------------------|------------------------|---------------------------|---------|
| No. of males/total (%)  | 9/9 (100)              | 34/40 (85)                | 0.577   |
| Mean age (yr) ± SD     | 44 ± 12                | 44 ± 14                   | 0.912   |
| No. HIV infected/total (%) | 7/9 (78)            | 30/40 (75)                | 1.000   |
| No. HIV positive with antiretroviral therapy/total (%) | 2/7 (29)             | 12/29 (41)                 | 0.681   |
| No. born in Africa/total (%) | 1/9 (11)           | 4/40 (10)                 | 1.000   |
| Presentation at baseline |                        |                           |         |
| No. with disseminated disease/total (%) | 24/40 (60)       | 0.454                     |         |
| No. with high serum antigen titer (≥ 512)/total (%) | 5/9 (56)            | 17/38 (45)                 | 0.715   |
| No. with meningitis/total (%) | 9/9 (100)          | 29/34 (83)                 | 0.319   |
| No. with abnormal neurology/total (%) | 4/9 (44)            | 15/40 (37.5)               | 0.720   |
| No. with abnormal brain imaging/total (%) | 4/9 (44)            | 13/36 (37)                 | 0.716   |
| No. with mycological failure at day 15/total (%) | 5/9 (56)            | 8/29 (26)                  | 1.000   |
| No. who died within 90 days after diagnosis/total (%) | 0/8                 | 10/32 (31.2)               | 0.126   |

<sup>a</sup> Total number of patients evaluated or for whom the information was available.

<sup>b</sup> Persistence of viable cryptococi in cultured samples.

![FIG 1](comparison_of_dna_contents_and_virulence_of_haploid_and_diploid_strains)

FIG 1 Comparison of DNA contents and virulence of haploid and diploid Aα C. neoformans isolates recovered during human or murine infections. (A) Cells were stained with propidium iodide to measure DNA content in comparison with that of reference haploid strain H99. Ploidy was determined for single-colony isolates (AD 7-99 and AD 8-18) purified from clinical sample AD 1-77, as well as a single colony (AD 10-30) recovered from the brain of a mouse inoculated with AD 7-99. (B) Three groups of seven outbred male mice were inoculated intravenously with 10⁶ cells of haploid (AD 7-99) or diploid (AD 8-18) strains purified from the clinical sample or the diploid strain AD 10-30 recovered from the mouse brain. Differences in survival were analyzed using Stata (SE) version 10 (Stata Corporation, College Station, TX). The strains of clinical origin showed no statistically significant differences in virulence (P = 0.056). Mice infected with the diploid strain of murine origin (AD 10-30) survived significantly longer than did mice infected with the strains of clinical origin (P < 0.001, log-rank test).

or with one of the mouse-derived diploid Aα strains. Out of the 405 colonies studied from brain and lung homogenates plated at various times after inoculation, one haploid colony was discovered. These data show that both positive and negative shifts in ploidy occur in vivo.

In vivo diploidization can result from endoreplication. For cell fusion to occur in vivo, different cell types need to interact. Experimental coinfection with KN99a and KN99α inoculated separately revealed that both cell types are visualized in close contact within capillaries (Fig. 2), showing that cell fusion is physically possible. Since ploidy changes could result from cell fusion or endoreplication, a nourseothricin (NAT)-resistant isolate (AD 1-25) was constructed from the wild-type AD 7-99 strain. Analysis of DNA content by flow cytometry following coinfection of six mice with the NAT-resistant and wild-type strains resulted in 11.9% (30/251) diploid NAT-resistant single colonies. These diploid isolates were found in both brains and lungs at days 7 and 15 postinoculation. Quantitative PCR analysis of 30 diploid and six haploid NAT-resistant single-colony isolates was used to determine whether diploid isolates had the same (endoreplication) or half (cell fusion) the amount of NAT DNA compared to a control region of the genome present in both cell types (chitin synthase, CHS1). Quantitative PCR analysis resulted in equivalent gene copy numbers in both the diploid and haploid isolates (mean crossing point ratio between amplification of the CHS1 gene and the NAT gene = 1.03 ± 0.02 for both haploid and diploid strains [Table 3]), suggesting that the diploid strains resulted from endoreplication and not cell fusion.

DISCUSSION

The concept of one strain/one infection is assumed to be valid for the majority of infectious diseases. Recent studies have used determination of susceptibility to anti-infective drugs, sequence-based approaches, and metagenomic analyses to assess microbial diversity during infection or colonization (31, 32). There is evidence that infections with a number of bacteria, viruses, and parasites may not be clonal. Coinfection with strains of Plasmodium falciparum exhibiting different patterns of susceptibility to anti-malarial drugs are correlated with treatment failure (33). Shigella flexneri strains with multiple plasmids suggest polyclonal infections (34). Sputum samples from patients with active tuberculosis have been shown to contain multiple strains of Mycobacterium tuberculosis (35). Different strains of hepatitis C virus or HIV,
possibly representing mixed infections, superinfections, or quasispecies in the host, have been found in a single patient (36, 37). Here we showed that almost 20% of cryptococcosis cases were associated with multiple strains of the fungal pathogen *C. neoformans*.

Only anecdotal reports of mixed infections have been published previously (6–11). Previous experiments with mice showed that infection with multiple strains of *C. neoformans* inoculated via the intranasal or intravenous route can result in mixed infections in the lungs and/or brain (15, 38, 39). The presence of multiple strains in the environment makes it likely that multiple infections could have resulted from either coinfestation with different strains or *in vivo* diploidization. This diploidization could occur through same-sex cell fusion or endoreplication. Coinfection with both haploid and diploid strains could also follow ploidy changes in the environment (21). However, the discovery of stable diploid isolates in murine tissues following inoculation of an *Aa* haploid isolate demonstrated that changes in ploidy can occur *in vivo*. Previous studies using laboratory-derived isolates had not observed *in vivo* diploidization (29). Our observation of diploidization in clinical isolates is likely due to the overall fitness of the newly isolated clinical strains and their limited subculture in the laboratory. The sources of mixed infections are thus multiple simultaneous or sequential infestations from the environment, as well as ploidy changes during infection progression.

Coinfection with a wild-type *Aa* haploid isolate and an *NAT*-resistant diploid isolate from infected tissues (both mating type *A*) in the majority of patients (6, 20, 27). Furthermore, an experimental model of cryptococcosis has shown that the presence of an established cryptococcal infection does not prevent infection with a second strain, although it can alter the kinetics of the infection (38). The scarcity of mixed-infection reports could also be due to technical bias.

Indeed, the routine clinical practice of analyzing single-colony isolates obtained from a single anatomical site would make the discovery of mixed infections unlikely.

In cases where genetically related haploid and diploid strains were found during the course of infection in the same patient, it was important to determine the origin of the diploid strain. These infections could have resulted from either cointestation with different strains or *in vivo* diploidization. This diploidization could occur through same-sex cell fusion or endoreplication. Coinfection with both haploid and diploid strains could also follow ploidy changes in the environment (21). However, the discovery of stable diploid isolates in murine tissues following inoculation of an *Aa* haploid isolate demonstrated that changes in ploidy can occur *in vivo*. Previous studies using laboratory-derived isolates had not observed *in vivo* diploidization (29). Our observation of diploidization in clinical isolates is likely due to the overall fitness of the newly isolated clinical strains and their limited subculture in the laboratory. The sources of mixed infections are thus multiple simultaneous or sequential infestations from the environment, as well as ploidy changes during infection progression.

Inoculation of differentially labeled strains and the observation of their proximity within host capillaries show that *in vivo* cell fusion is physically possible. Same-sex fusion has been described *in vitro* for both *C. neoformans* var. *neoformans* (both mating types) and *C. neoformans* var. *grubii* (mating type *a*) (22, 23). Coinfection with a wild-type *Aa* haploid isolate and an *NAT*-resistant haploid AD 1–25

| Strain(s) and DNA amt | CHS1 Cp<sup>a</sup> | NAT Cp | CHS1/NAT Cp ratio |
|-----------------------|---------------------|--------|-------------------|
| NAT-resistant haploid AD 1–25 | | | |
| 100 ng | 23.99 | 23.12 | 1.038 |
| 50 ng | 25.29 | 24.99 | 1.012 |
| 20 ng | 28.69 | 27.58 | 1.040 |
| 10 ng | 29.70 | 28.54 | 1.041 |
| 5 ng | 30.89 | 29.88 | 1.034 |
| 2 ng | 32.79 | 31.56 | 1.039 |
| 1 ng | 34.78 | 32.48 | 1.071 |
| Wild-type haploid AD 7–99 | 26.27 | 35 | |
| NAT-resistant haploid isolates from infected tissues (n = 6)<sup>b</sup> | 27.35 ± 1.48 | 26.43 ± 1.38 | 1.03 ± 0.02 |
| NAT-resistant diploid isolates from infected tissues (n = 30)<sup>b</sup> | 26.43 ± 2.00 | 25.59 ± 1.78 | 1.03 ± 0.02 |

<sup>a</sup> Cp, crossing point.

<sup>b</sup> Values are means ± standard deviations.
resistant construct was used to elucidate whether diploidization in vivo resulted from cell fusion and/or endoreplication. Of the 30 diploid NAT-resistant isolates from infected tissue that we analyzed, all had two copies of the NAT gene, suggesting that the observed diploidization was due to endoreplication. In a recent report, ploidy changes leading to the production of titan cells with up to eight times the normal DNA content were observed in the lungs of mice (40). It remains unclear whether the diploidization observed in our clinical isolates is related to titan cell formation or occurs via another, unrelated, process.

The demonstration that shuttling between diploid and haploid states occurred in vivo reinforced recent findings obtained in vitro (21). A mixture of both populations may provide better adaptation to the environment in nature and in the host. Lin and colleagues found that autodiploids represent the most common type of diploid in C. neoformans populations in the environment and suggested that their function may be to generate genetic diversity de novo during the sexual cycle (21). The ability to produce diploid cells may prove beneficial to cryptococcal cells by allowing rapid evolution of genes (20, 21) or by increasing drug resistance, as shown in Candida albicans (41) in response to environmental and host challenges. While we did not detect differences in antifungal susceptibility profiles between our Aa haploid and diploid strains (data not shown), we cannot rule out the possibility that ploidy changes in other strains could explain some treatment failures (Table 2). Interestingly, while drug treatment failure rates may increase in patients with mixed infections, death rates may also decrease, although neither characteristic reached statistical significance. These paradoxical findings could be explained by interactions between coinfecting strains that have been shown to decrease pathogenesis in experimental models (15). However, the relatively small number of patients studied here prevents definitive conclusions about a relationship between a mixed infection and the outcome of the infection. Further studies of humans and in the experimental models are needed to explore this hypothesis.

The discovery that mixed infections are common is a major finding for the management of cryptococcosis and other infections, especially those with environmentally acquired fungi, such as Histoplasma capsulatum, Blastomyces dermatitidis, and Aspergillus spp. Future drug design—including vaccine—strategies need to take into account the complex nature of cryptococcal infections. The use of unpurified clinical isolates was vital to these experiments. Thus, while Koch’s postulates can be used to define a specific organism causing a specific class of disease—such as C. neoformans causing cryptococcosis—care should be taken in extrapolating these postulates to the clinical setting. Our data suggest, in the context of fungal infections, that clonal infections can cause disease but clinical disease is not always caused by clonal infections. This concept may apply broadly to other microbes and should be considered in the current era when a multiplicity of new tools and approaches can be used to determine the clonality of infections.

C. neoformans strains. Clinical cultures were collected during the prospective multicenter CryptoA/D study implemented at the National Reference Center for Mycoses and Antifungals (NRCMA) between 1997 and 2001 (30). The study was approved by the local ethical committee and reported to the French Ministry of Health (registration no. DGS970089). Patients enrolled in the CryptoA/D study gave written informed consent for a systematic workup. This included cultures from CSF, blood, and urine samples, as well as cultures from skin lesions or BAL fluid when appropriate. Original cultures correspond to the cultures obtained in each clinical mycology laboratory after culture of the biological specimens on agar plates or in tubes. These original cultures were directly sent to the NRCMA prior to any purification step or freezing. The original cultures were not purified prior to storage at −80°C and serotyping at the NRCMA. The selection of the 30 original cultures used for the present study was “random” (on a first found/first studied basis) and not based on the patients’ characteristics or serotyping results. When available, all of the original cultures from the same patient (recovered from different anatomical sites and at different times during the episode of cryptococcosis) were analyzed. A suspension of approximately 105 cells/ml from the original culture was plated on Sabouraud agar plates. Single CFU resulting from the multiplication of a single cell were subcultured for further analysis.

The following C. neoformans laboratory reference strains were used for comparison: JEC21 (serotype D MATa [42]), B3502 (serotype D MATa [43]), H99 (serotype A MATa [44]), KN99a (serotype A MATa), and KN99a (serotype A MATa [19]).

Determination of ploidy using flow cytometry. Cells were prepared for flow cytometry by using the protocol described previously (45). Data were acquired from 30,000 cells using the FL2 channel of a BD FACScan flow cytometer (Becton Dickinson & Company, Franklin Lakes, NJ). The fluorescence-activated cell sorter profile of original cultures or single-colony isolates was compared with that obtained with haploid reference strain H99a to determine ploidy. Analysis was performed using CellQuest software version 3.3 (BD Biosciences, San Jose, CA).

Determination of mating type and serotype using MAT/serotype-specific primers. Original cultures and single-colony isolates were grown for 24 h at 28°C on solid yeast nitrogen base medium. DNA was extracted using the High Pure PCR template preparation kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s instructions. PCRs were performed on an iCycler thermocycler (Bio-Rad, Hercules, CA) using primers specific for the serotype A or D SXI1/SXI2 and STE20a/a loci to determine the mating type and serotype (25). Results were confirmed using serotype-specific primers for the PAK1 and GPA1 genes on all original cultures and selected single-colony isolates (25). Laboratory reference strains were used as positive controls.

MLST. MLST was performed on all Aa isolates from patients with mixed infections. Eight MLST loci (CAP59, URA5, GPD1, SOD1, LAC1, IGS1, PLB1, and TEF1), including six loci described for C. neoformans var. grubii by Litvinseva et al. (46) and two chosen by the Ishaam cryptococcal genotyping working group (47), were examined. Both strains of purified amplified fragments were sequenced at the sequencing facility (PE-8) of the Institut Pasteur on an ABI Prism 3700 DNA analyzer (Applied Biosystems, Courtaboeuf, France), with the same primers that were used in the PCR steps. Sequences edited with Chromas Pro version 1.41 (Technelysium Pty. Ltd., Helensvale, Queensland, Australia) were compared with the allele sequences of the C. neoformans var. grubii MLST database (http://cneofomans.mlst.net/), and new allelic sequences were submitted.

For serotype D, MLST profiles were determined for the same eight loci. The same primers were used for the PCR amplification and sequencing of seven loci (CAP59, URA5, GPD1, LAC1, IGS1, PLB1, and TEF1), but for SOD1, new primers were designed based on the JEC21 sequences (GenBank accession no. AE017344) (Table 4). For the eight loci, the PCR conditions and the start and end points of the sequences were the same as those for serotype A. The serotype D MLST database is being currently developed at the Imperial College London, and MLST allelic sequences for

MATERIALS AND METHODS

Ethics statement. The CryptoA/D study was approved by the local ethical committee and reported to the French Ministry of Health (registration no. DGS970089). Patients enrolled in the CryptoA/D study gave written informed consent for a systematic workup. Data were analyzed anonymously. All animal experiments were done in accordance with the Institut Pasteur’s institutional guidelines (approved protocol CHST no. 03-144).

April 2010 Volume 1 Issue 1 e00091-10
serotype D were numbered after discussion with the Isham cryptococcal genotyping working group and will be available online when the serotype D MLST database is established.

For AD hybrid isolates, portions of the CAP10 and URE1 loci were amplified according to Lin et al. (27). The MLST locus SOD1, amplified with serotype A-specific primers, was also analyzed. In order to improve the typing method for the AD hybrid isolates, new primers specific for serotype A were designed for the PLB1 and TEF1 loci (Table 4). For the design of these new primers, nucleotide sequences of serotype D strain B3501 (GenBank accession no. AF238241 for locus PLB1 and positions 355113 to 355970 of the contig chr13.b3501.040506 from the Stanford database [http://www-sequence.stanford.edu/group/C.neoformans/index.html] for locus TEF1) and serotype A strain H99 (GenBank accession no. AF223383 for locus PLB1 or M1-106 (GenBank accession no. U81804 for locus TEF1) were compared. The PCR conditions were modified as follows: 35 cycles of annealing at 52°C for PLB1 and 58°C for TEF1 and then elongation at 72°C for 1 min. For the SOD1, PLB1, and TEF1 loci, sequences were also compared with the allele sequences of the MLST database.

**NAT-resistant isolate construction.** An NAT-resistant isolate of AD 7-99 was generated by gene insertion as previously described (15, 48). The NAT transgene (NAT) was inserted into a noncoding region downstream of the LYS2 gene coding region located on chromosome 5. PCR was used to generate the 5′′ (KN0140 and KN0129) and 3′′ (KN0139 and KN0122) flanking regions containing linkers to a NAT′′ cassette, and overlap PCR was used to generate the full-length NAT insertion construct (Table 4). The insertion construct was introduced by biologic transformation into AD 7-99 to generate NAT-resistant strain AD 1-25. Proper insertion was verified by PCR using primers external to the integration site (KN0177 and KN0176) and Southern hybridization (not shown).

**Experimental infections.** Yeast suspensions for inoculation were prepared and found to be equivalent. Mice (Charles River, L’Arbresle, France) were inoculated intravenously. Mice were euthanized by CO2 inhalation, and organs were removed, homogenized, and plated on Sabouraud agar containing 0.5 mg/ml chloramphenicol and YPD agar containing NAT at 100 µg/ml.

**Statistics.** Survival studies were analyzed with a log rank test. Coinfection was analyzed using Fisher’s exact test.

### TABLE 4 Sequences of primers designed for MLST locus SOD1 for serotype D, for MLST loci PLB1 and TEF1 for serotype A, for NAT insertion, and for quantitative PCR

| Locus  | Primer       | Sequence (5′−3′)   | Amplicon size (bp) |
|--------|--------------|--------------------|--------------------|
| SOD1   | SOD1Dr       | TCTAGTCAAAATGGTCAAGG | 643                |
|        | SOD1Df       | GGCACGGCTTGGTGAAGCG |                    |
| PLB1   | PLB1serAf    | GCCACAGGTACTTGGC    | 821                |
|        | PLB1serAr    | GCTGCGGTTAAAAATCGAG |                    |
| TEF1   | TEF1f        | AATCGTCAAGGAGACCAAG | 993                |
|        | TEF1r        | GCTTCTCCATCGGAGTTC  |                    |
| 5′ flanking region for NAT insertion | KN0140 | TGCATACATCTGGCAAGCACACAGAGATTGACCCCC |        |
|        | KN0129       | GCAACCTTTGGTTAGGAGGC |                |
| 3′ flanking region for NAT insertion | KN0139 | CCGTTAAAATACAGATAAACCCGAAAGGACCAGTCAAGT |        |
|        | KN0122       | AACCTGACGGAAGAGGCAAA |                |
| Outside 5′ integration check | KN0177 | CTGCTCATCAAACCTAGCAAGTTC |        |
|        | KN0176       | CTCGAGACCAAGATCAAGATTGCC |             |
| CHS1   | CHS1f        | GTCCACAGGGAGGACTCTTTC | 168               |
|        | CHS1r        | TGCTGTTCACTGGCCATGGG |                    |
| NAT    | KN0192       | GGTGACCGCGGAGACGCGTG | 123                |
|        | MD001        | GATGAGCCGCGCCGCGCCT |                    |

Mixed Infection and In Vivo Evolution of C. neoformans

April 2010 Volume 1 Issue 1 e00091-10
To check whether diploid strains were stable in vivo or were only a transient stage, two groups of seven mice were inoculated with the diploid strain recovered from the clinical culture (AD 8-18) and from the mouse brain (AD 10-30). Mice were sacrificed at 3, 7, and 15 days postinoculation. Lungs and brains were removed, homogenized, and plated on Sabouraud-chloramphenicol agar. CFU were enumerated, and single-colony isolates (at least 16 per organ) were analyzed as described above for ploidy determination.

Quantitative PCR. To determine if diploid isolates resulted from endoreplication or cell fusion between AD 7-99 (wild-type isolate) and AD 1-25 (NAT resistant), quantitative PCR was performed. DNA was generated by cell fusion between AD 7-99 and AD 1-25 would have only a single copy. Quantitative PCR was performed with a LightCycler LC480 (Roche Applied Science, Germany) in a final volume of 20 μl containing 0.75 μl of each primer at 10 μM, 10 μl of 50 μM green master mix 2X, 9.25 μl of water, and 2 μl of DNA. The conditions were similar for the amplification of both the CHS1 and NAT insertions: 5 min at 95°C, 40 cycles of 15 s at 95°C and 60 s at 60°C, and then 1 min at 95°C and 1 min at 60°C with a melting curve temperature range of 55°C to 95°C. Haploid parental strain AD 1-25 was used for a standard curve using known DNA amounts of 100 ng, 50 ng, 20 ng, 10 ng, 5 ng, 2 ng, and 1 ng determined with a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific). For each isolate, the ratio of the crossing points obtained for amplification of the CHS1 gene and the NAT gene was calculated to determine if the diploid isolates had the same (endoreplication) or half (cell fusion) the amount of NAT DNA compared to CHS1 DNA.

Statistical analysis. Comparisons between groups were done using chi-square or Fisher’s exact tests for categorical variables and Student’s t test or one-way analysis of variance for continuous variables. Survival curves were compared by the log-rank test. Data were analyzed using Stata Statistical Software (Stata 10.0; Stata Corporation, College Station, TX). P values of less than 0.05 were considered significant.

Acknowledgments

We gratefully acknowledge the technical help of Dorothee Raoux in the molecular Mycology Unit, Laure Diancourt and Coralie Tran at the sequencing facility (PF-8, Genotyping of pathogens and Public Health), and Marie-Christine Wagner at the flow cytometry facility (Institut Pasteur). We also thank Sitali Simwami and Matthew Fisher (Imperial College London) for C. neoformans MLST allele designation and Frederique Vernel-Paulillac and Stéphane Bregt (Molecular Mycology Unit, Institut Pasteur) for helpful discussion.

The financial contributions of the Institut Pasteur (through the Programme de Recherche Clinique), the Institut de Veille Sanitaire (through the National Reference Center for Mycoses and Antifungals), and the Ensemble contre le sida-SIDACTION (through a grant to F.D.) are gratefully acknowledged. Work in the Nielsen laboratory was funded by National Institutes of Health K22 grant AI070152.

The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

We have no conflicts of interest.

References

1. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
2. Park, B. J., K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, and T. M. Chiller. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530.
3. Franzot, S. P., J. S. Hamdan, B. P. Currie, and A. Casadevall. 1997. Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J. Clin. Microbiol. 35:2243–2251.
4. Garcia-Hermoso, D., S. Mathoulin-Pelissier, B. Couprie, O. Ronin, B. Dupont, and F. Dromer. 1997. DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D, J. Clin. Microbiol. 35:2683–2685.
5. Krajden, S., R. C. Summerbell, J. Kane, I. F. Salkin, M. E. Kenna, M. G. Rinaldi, M. Fuska, E. Spratt, C. Rodriguez, et al. 1991. Normally saprobe cryptococci isolated from Cryptococcus neoformans infections. J. Clin. Microbiol. 29:1883–1887.
6. Mandal, P., U. Banerjee, A. Casadevall, and J. D. Nosanchuk. 2005. Dual infections with pigmented and albino strains of Cryptococcus neoformans in patients with or without human immunodeficiency virus infection in India. J. Clin. Microbiol. 43:4766–4772.
7. Haynes, K. A., D. J. Sullivan, D. C. Coleman, J. C. Clarke, R. Emilianus, C. Atkinson, and K. J. Ann. 1995. Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting. J. Clin. Microbiol. 33:99–102.
8. Igreja, R. P., S. Lazerà Mdos, B. Wanke, M. C. Galhardo, S. E. Kidd, and W. Meyer. 2004. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro. Med. Mycol. 42:229–238.
9. Jain, N., B. L. Wickes, S. M. Keller, J. Fu, A. Casadevall, P. Jain, M. A. Ragan, U. Banerjee, and B. C. Fries. 2005. Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J. Clin. Microbiol. 43:5733–5742.
10. Litvintseva, A. P., L. Kestenbaum, R. Vilgalys, and T. G. Mitchell. 2005. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J. Clin. Microbiol. 43:556–564.
11. Sullivan, D., K. Haynes, G. Moran, D. Shanley, and D. Coleman. 1996. Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. J. Clin. Microbiol. 34:1739–1744.
12. Blasi, E., A. Brozzetti, D. Francisci, R. Neglia, G. Cardinali, F. Bistoni, V. Vidotto, and F. Balldi. 2001. Evidence of microevolution in a clinical case of recurrent Cryptococcus neoformans meningoencephalitis. Eur. J. Clin. Microbiol. Infect. Dis. 20:535–543.
13. Franzot, S. P., J. Mukherjee, R. Cherniak, L. C. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89–97.
14. Garcia-Hermoso, D., F. Dromer, and G. Janbon. 2004. Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect. Immun. 72:3359–3365.
15. Nielsen, K., G. M. Cox, A. P. Litvintseva, E. Mylonakis, S. D. Malliaris, D. K. Benjamin, Jr., S. S. Giles, T. G. Mitchell, A. Casadevall, J. R. Perfect, and J. Heitman. 2005. Cryptococcus neoformans α strains preferentially disseminate to the central nervous system during confection. Infect. Immun. 73:4922–4933.
16. Hull, C. M., R. M. Raisner, and A. D. Johnson. 2000. Evidence for mating of the “asexual” yeast Candida albicans in a mammalian host. Science 289:307–310.
17. Kwon-Chung, K. J. 1975. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 67:1197–1200.
18. Magee, B., and P. Magee. 2000. Induction of mating in Candida albicans by construction of MTLa and MTLa/α strains. Science 289:310–313.
19. Nielsen, K., G. M. Cox, P. Wang, D. L. Toffaletti, J. R. Perfect, and J. Heitman. 2003. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and α isolates. Infect. Immun. 71:4831–4841.
20. Lin, X., C. M. Hull, and J. Heitman. 2005. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434:1017–1021.
21. Lin, X., S. Patel, A. P. Litvintseva, A. Floyd, T. G. Mitchell, and J. Heitman. 2009. Diploids in the Cryptococcus neoformans serotype A population homozygous for the alpha mating type originate via unisexual mating. PLoS Pathog. 5:e1000283.
22. Tschirke, R. L., M. Lazerà, Y. C. Chang, B. L. Wickes, and K. J.
Kwon-Chung. 2003. Haploid fruiting in Cryptococcus neoformans is not mating type alpha-specific. Fungal Genet. Biol. 39:230–237.

23. Wickes, B. L., M. E. Mayorga, U. Edman, and J. C. Edman. 1996. Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the alpha-mating type. Proc. Natl. Acad. Sci. U. S. A. 93:7327–7331.

24. Boekhout, T., B. Theelen, M. Diaz, J. W. Fell, W. G. Hop, E. C. Abeln, F. Dromer, and W. Meyer. 2001. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147:891–907.

25. Lengeler, K. B., G. M. Cox, and J. Heitman. 2001. Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus. Infect. Immun. 69:115–122.

26. Cologlioni, C., M. C. Esposto, A. M. Tortorano, and M. A. Viviani. 2006. Cryptococcus neoformans population includes hybrid strains homozygous at mating-type locus, FEMS Yeast Res. 6:608–613.

27. Lin, X., A. P. Litvintseva, K. Nielsen, S. Patel, A. Floyd, T. G. Mitchell, and J. Heitman. 2007. αΔα hybrids of Cryptococcus neoformans: evidence of same-sex mating in nature and hybrid fitness. PLoS Genet. 3:1975–1990.

28. Alby, K., D. Schafer, and R. J. Bennett. 2009. Homothallic and heterothallic mating in the opportunistic pathogen Candida albicans. Nature 460:890–893.

29. Lin, X., K. Nielsen, S. Patel, and J. Heitman. 2008. Impact of mating type, serotype, and ploidy on the virulence of Cryptococcus neoformans. Infect. Immun. 76:2923–2938.

30. Dromer, F., S. Mathoulin-Pelissier, O. Launay, and O. Lortholary. 2007. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 4:e21.

31. Brogden, K. A., J. M. Guthmiller, and C. E. Taylor. 2005. Human polymicrobial infections. Lancet 365:253–265.

32. Gill, S. R., M. Pop, R. T. Deboy, P. B. Eckburg, P. J. Turnbaugh, B. S. Samuel, J. I. Gordon, D. A. Relman, C. M. Fraser-Liggett, and K. E. Nelson. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359.

33. Lee, S. A., A. Yeka, S. L. Nsobya, C. Dokomajilar, P. J. Rosenthal, A. Talisuna, and G. Dorsey. 2006. Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J. Infect. Dis. 193:1160–1163.

34. Tacket, C. O., N. Shahid, M. I. Huq, A. R. Alim, and M. L. Cohen. 1984. Usefulness of plasmid profiles for differentiation of Shigella isolates in Bangladesh. J. Clin. Microbiol. 20:300–301.

35. Warren, R. M., T. C. Victor, E. M. Streicher, M. Richardson, N. Beyers, N. C. Gey van Pittius, and P. D. van Helden. 2004. Patients with active tuberculosis often have different strains in the same sputum specimen. Am. J. Respir. Crit. Care Med. 169:610–614.

36. Altfeld, M., T. M. Allen, X. G. Yu, M. N. Johnston, D. Agrawal, B. T. Korber, D. C. Montefiori, D. H. O’Connor, B. T. Davis, P. K. Lee, E. L. Maier, J. Harlow, P. J.oulder, C. Brander, E. S. Rosenberg, and B. D. Walker. 2002. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420:434–439.

37. Ghosn, J., V. Thibault, C. Delaugerre, H. Fontaine, O. Lortholary, C. Rouzioux, S. Pol, and M. L. Chais. 2008. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men. AIDS 22:658–661.

38. Charlier, C., K. Nielsen, S. Daou, M. Brigitte, F. Chretien, and F. Dromer. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77:120–127.

39. Nelson, R. T., J. Hua, B. Pryor, and J. K. Lodge. 2001. Identification of virulence mutants of the fungal pathogen Cryptococcus neoformans using signature-tagged mutagenesis. Genetics 157:935–947.

40. Okagaki, L., A. Strain, J. Nielsen, C. Charlier, N. Baltes, F. Chretien, J. Heitman, F. Dromer, and K. Nielsen. Cryptococcal cell morphology affects cell contacts and pathogenicity. PLoS Pathog., in press.

41. Selmecki, A., A. Forche, and J. Berman. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367–370.

42. Heitman, J., B. Allen, J. A. Alspaugh, and K. J. Kwon-Chung. 1999. On the origins of congeneric MATalpha and MATa strains of the pathogenic yeast Cryptococcus neoformans. Fungal Genet. Biol. 28:1–5.

43. Kwon-Chung, K. J., J. C. Edman, and B. L. Wickes. 1992. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect. Immun. 60:602–605.

44. Perfect, J. R., S. D. Lang, and D. T. Durack. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am. J. Pathol. 101:177–194.

45. Sia, R. A., K. B. Lengeler, and J. Heitman. 2000. Diploid strains of the pathogenic basidiomycete Cryptococcus neoformans are thermally dimorphic. Fungal Genet. Biol. 29:153–163.

46. Litvintseva, A. P., R. Thakur, R. Vilgalys, and T. G. Mitchell. 2006. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172:2223–2238.

47. Meyer, W., D. M. Aanensen, T. Boekhout, M. Cogliati, M. R. Diaz, M. C. Esposto, M. Fisher, F. Gilgado, F. Hagen, S. Kooscharoen, A. P. Litvintseva, T. G. Mitchell, S. P. Simwami, L. Trilles, M. A. Viviani, and J. Kwon-Chung. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med. Mycol. 47:561–570.

48. Fraser, J. A., R. L. Subaran, C. B. Nichols, and J. Heitman. 2003. Recaptulation of the sexual cycle of the primary fungal pathogen Cryptococcus neoformans var. gattii: implications for an outbreak on Vancouver Island, Canada. Eukaryot. Cell 2:1036–1045.